$同源康医药-B(0_老虎社区_美港股上老虎

$同源康医药-B(02410)$ 据中期业绩披露，核心产品TY-9591的NDA申请已完成第三轮技术审评，目前处于最后审评阶段，预计2026年9月下旬即可正式获批

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":603954846924856,"tweetId":"603954846924856","gmtCreate":1788486866851,"gmtModify":1788486869138,"author":{"id":4193625296607780,"idStr":"4193625296607780","authorId":4193625296607780,"authorIdStr":"4193625296607780","name":"打铁不如李铁","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 据中期业绩披露，核心产品TY-9591的NDA申请已完成第三轮技术审评，目前处于最后审评阶段，预计2026年9月下旬即可正式获批</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02410\">$同源康医药-B(02410)$ </a> 据中期业绩披露，核心产品TY-9591的NDA申请已完成第三轮技术审评，目前处于最后审评阶段，预计2026年9月下旬即可正式获批</p></body></html>","text":"$同源康医药-B(02410)$ 据中期业绩披露，核心产品TY-9591的NDA申请已完成第三轮技术审评，目前处于最后审评阶段，预计2026年9月下旬即可正式获批","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/603954846924856","repostId":0,"isVote":1,"tweetType":1,"viewCount":39,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02410"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":131,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}